Connor, Clark & Lunn Investment Management (CC&L)
RIGL icon

Connor, Clark & Lunn Investment Management (CC&L)’s Rigel Pharmaceuticals RIGL Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.92M Sell
49,096
-34,033
-41% -$1.05M ﹤0.01% 1016
2026
Q1 		$2.25M Sell
83,129
-24,840
-23% -$835K 0.01% 927
2025
Q4 		$4.62M Sell
107,969
-120,426
-53% -$4.54M 0.01% 666
2025
Q3 		$6.47M Buy
228,395
+80,212
+54% +$2.4M 0.02% 512
2025
Q2 		$2.78M Sell
148,183
-9,741
-6% -$185K 0.01% 761
2025
Q1 		$2.84M Buy
157,924
+18,796
+14% +$381K 0.01% 641
2024
Q4 		$2.34M Buy
139,128
+41,122
+42% +$789K 0.01% 679
2024
Q3 		$1.59M Buy
98,006
+22,443
+30% +$264K 0.01% 729
2024
Q2 		$621K Buy
75,563
+2,307
+3% +$24.1K ﹤0.01% 993
2024
Q1 		$1.08M Buy
73,256
+14,355
+24% +$193K ﹤0.01% 858
2023
Q4 		$854K Sell
58,901
-262
-0.4% -$2.68K ﹤0.01% 903
2023
Q3 		$639K Sell
59,163
-896
-1% -$10.8K ﹤0.01% 958
2023
Q2 		$775K Buy
60,059
+1,720
+3% +$23.3K ﹤0.01% 870
2023
Q1 		$770K Buy
58,339
+1,060
+2% +$16.8K ﹤0.01% 782
2022
Q4 		$859K Buy
+57,279
New +$525K ﹤0.01% 743
2017
Q4 		– Sell
-1,014
Closed -$26K – 843
2017
Q3 		$26K Sell
1,014
-11,778
-92% -$286K ﹤0.01% 797
2017
Q2 		$349K Sell
12,792
-8,473
-40% -$232K ﹤0.01% 661
2017
Q1 		$704K Sell
21,265
-1,849
-8% -$47.1K ﹤0.01% 560
2016
Q4 		$550K Sell
23,114
-8,920
-28% -$255K ﹤0.01% 586
2016
Q3 		$1.18M Sell
32,034
-10,920
-25% -$313K 0.01% 450
2016
Q2 		$958K Hold
42,954
– – 0.01% 472
2016
Q1 		$893K Sell
42,954
-3,113
-7% -$76.8K 0.01% 475
2015
Q4 		$1.4M Buy
46,067
+5,822
+14% +$177K 0.01% 392
2015
Q3 		$994K Buy
40,245
+15,585
+63% +$465K 0.01% 402
2015
Q2 		$792K Buy
24,660
+10,120
+70% +$387K 0.01% 367
2015
Q1 		$519K Buy
14,540
+12,630
+661% +$346K ﹤0.01% 388
2014
Q4 		$43K Buy
+1,910
New +$38.6K ﹤0.01% 568
2014
Q2 		– Sell
-2,162
Closed -$93K – 617
2014
Q1 		$93K Buy
+2,162
New +$77.1K ﹤0.01% 653

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s RIGL Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Rigel Pharmaceuticals (RIGL) stake by 41% in Q2 2026, selling an estimated $1.05M and leaving 49,096 shares worth $1.92M. The position accounts for ﹤0.01% of the portfolio, ranked #1016.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in RIGL in Q1 2014 and has held it in 28 quarters since. The position peaked at $6.47M in Q3 2025. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 49,096 shares of Rigel Pharmaceuticals worth $1.92M as of Q2 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 34,033 Rigel Pharmaceuticals shares in Q2 2026, an estimated $1.05M.
  • Rigel Pharmaceuticals made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #1016 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Rigel Pharmaceuticals in Q1 2014 and has held it in 28 quarters since.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Rigel Pharmaceuticals position peaked at $6.47M in Q3 2025.
  • 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.